| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00259-007-0446-X |
| P698 | PubMed publication ID | 17479261 |
| P2093 | author name string | Rakesh Kumar | |
| P2860 | cites work | Early changes in [18F]FLT uptake after chemotherapy: an experimental study | Q44192327 |
| 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas | Q45144547 | ||
| The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels | Q46404885 | ||
| Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo | Q46495676 | ||
| Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods | Q46788429 | ||
| Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. | Q46790517 | ||
| Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. | Q46872269 | ||
| Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. | Q53496753 | ||
| PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. | Q53506378 | ||
| Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. | Q54117465 | ||
| Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation | Q56786765 | ||
| Residual mass in lymphoma may not be residual disease | Q68371464 | ||
| Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose? | Q83834919 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. | Q34363872 | ||
| Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas | Q35920204 | ||
| The role of functional and molecular imaging in cancer drug discovery and development | Q35968111 | ||
| Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. | Q40582151 | ||
| Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation | Q42502434 | ||
| Metabolic flare: indicator of hormone responsiveness in advanced breast cancer | Q43626747 | ||
| 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. | Q44030329 | ||
| Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. | Q44112084 | ||
| Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. | Q44128080 | ||
| Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies | Q44183097 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1334-1338 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Assessment of therapy response in malignant tumours with 18F-fluorothymidine. | |
| P478 | volume | 34 |
Search more.